Source: National Institutes of Health
Results of an early-stage clinical trial of an investigational malaria vaccine from Sanaria Inc., published in the journal Science, indicate that it is safe and effective in healthy adults. Researchers at the National Institute of Allergy and Infectious Diseases, Walter Reed Army Institute of Research, and the Naval Medical Research Center conducted the Phase I trial of 57 healthy adults between the ages of 18 and 45 who have never contracted malaria, 40 of whom received the PfSPZ Vaccine. Those who were vaccinated were divided into groups that received two to six intravenous doses at increasing dosages, with those receiving higher doses generating more antibodies and T cells. Both the vaccinated and control groups were exposed to bites from five mosquitoes carrying the malaria strain used to develop the vaccine, but none of the infections that occurred—in three out of 15 participants who received higher vaccine doses, 16 of the 17 participants who received lower doses, and 11 of the 12 participants in the control group who were not vaccinated—were related to the vaccine. However, the fact that the vaccine currently is administered intravenously poses a challenge for researchers
Copyright © 2014 Information, Inc.